Event-free survival at 12 months is a strong surrogate endpoint for stage 1 diffuse large B cell lymphoma: a report from Nation Wide Registry Thai Lymphoma Study Group

References

• Maurer MJ, Ghesquières H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066–1073.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Bachy E, Ghesquières H, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016;91(11):1096–1101.
   PubMed Web of Science ®Google Scholar
• Provencio M, Royuela A, Torrente M, et al. Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: a study report from the Spanish Lymphoma Oncology Group. Cancer. 2017;123(19):3709–3716.
   PubMed Web of Science ®Google Scholar
• Tracy SI, Larson MC, Feldman AL, et al. The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. Am J Hematol. 2019;94(6):658–666.
   PubMed Web of Science ®Google Scholar
• Biccler JL, Glimelius I, Eloranta S, et al. Relapse risk and loss of lifetime after modern combined modality treatment of young patients with Hodgkin lymphoma: a Nordic Lymphoma Epidemiology Group Study. J Clin Oncol. 2019;37(9):703–713.
   PubMed Web of Science ®Google Scholar
• Hapgood G, Zheng Y, Sehn LH, et al. Evaluation of the risk of relapse in classical Hodgkin lymphoma at event-free survival time points and survival comparison with the general population in British Columbia. J Clin Oncol. 2016;34(21):2493–2500.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Ellin F, Srour L, et al. International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma. J Clin Oncol. 2017;35(36):4019–4026.
   PubMed Web of Science ®Google Scholar
• Jakobsen LH, Bogsted M, Brown PN, et al. Minimal loss of lifetime for patients with diffuse large B-cell lymphoma in remission and event free 24 months after treatment: a Danish Population-Based Study. J Clin Oncol. 2017;35(7):778–784.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Habermann TM, Shi Q, et al. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol. 2018;29(8):1822–1827.
   PubMed Web of Science ®Google Scholar
• Giné E, Sehn LH. Diffuse large B-cell lymphoma: should limited-stage patients be treated differently? Hematol Oncol Clin North Am. 2016;30(6):1179–1194.
   PubMed Web of Science ®Google Scholar
• Kumar A, Lunning MA, Zhang Z, et al. Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era. Br J Haematol. 2015;171(5):776–783.
   PubMed Web of Science ®Google Scholar
• Chihara D, Oki Y, Fanale MA, et al. Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival? Ann Hematol. 2019;98(5):1169–1176.
   PubMed Web of Science ®Google Scholar
• Intragumtornchai T, Bunworasate U, Siritanaratkul N, et al. Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessability. Leuk Lymphoma. 2013;54(1):83–89.
   PubMed Web of Science ®Google Scholar
• Life tables by country: Thailand; 2020. Available from: http://apps.who.int/gho/data/view.main.61640?lang=en
   Google Scholar
• Jiménez-Ubieto A, Grande C, Caballero D, et al. Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma. Cancer Med. 2017;6(12):2766–2774.
   PubMed Web of Science ®Google Scholar
• Shi Q, Schmitz N, Ou FS, et al. Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: an individual patient-level analysis of multiple randomized trials (SEAL). J Clin Oncol. 2018;36(25):2593–2602.
   PubMed Web of Science ®Google Scholar
• van der Galiën HT, Hoogendoorn M, Kibbelaar RE, et al. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting. Ann Oncol. 2019;30(1):151–152.
   PubMed Web of Science ®Google Scholar
• Wudhikarn K, Bunworasate U, Julamanee J, et al. Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma. Hematol Oncol. 2019;37(5):578–585.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Kuhnt E, Trümper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013–1022.
   PubMed Web of Science ®Google Scholar
• Campbell BA, Connors JM, Gascoyne RD, et al. Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy. Cancer. 2012;118(17):4156–4165.
   PubMed Web of Science ®Google Scholar
• Poeschel V, Held G, Ziepert M, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394(10216):2271–2281.
   PubMed Web of Science ®Google Scholar
• Yoon DH, Sohn BS, Oh SY, et al. Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09). Oncotarget. 2017;8(8):13367–13374.
   PubMedGoogle Scholar
• Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008;26(14):2258–2263.
   PubMed Web of Science ®Google Scholar
• Lamy T, Damaj G, Soubeyran P, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2018;131(2):174–181.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Scott DW, Villa D, et al. Long-term follow-up of a PET-guided approach to treatment of limited-stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC). Blood. 2019;134(Suppl. 1):401.
   Google Scholar
• Persky DO, Li H, Stephens DM, et al. PET-directed therapy for patients with limited-stage diffuse large B-cell lymphoma – results of Intergroup NCTN Study S1001. Blood. 2019;134(Suppl. 1):349.
   Google Scholar
• Chihara D, Oki Y, Fanale MA, et al. Stage I non-Hodgkin lymphoma: difference in survival outcome by primary extranodal site of involvement. Br J Haematol. 2019;185(2):334–338.
   PubMed Web of Science ®Google Scholar
• Bunworasate U, Siritanaratanakul N, Khuhapinant A, et al. A nationwide prospective multicenter study of clinical features and outcomes of non-Hodgkin lymphoma in Thailand: an analysis of 939 cases. Blood. 2011;118(21):2064.
   Web of Science ®Google Scholar
• Blaker YN, Spetalen S, Brodtkorb M, et al. The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era. Br J Haematol. 2016;175(1):102–114.
   PubMed Web of Science ®Google Scholar
• Autio M, Leivonen S-K, Karjalainen-Lindsberg M-L, et al. Tumor microenvironment differs between germinal centre B-cell and non-germinal centre B-cell like diffuse large B-cell lymphomas and has subtype-specific prognostic impact on survival. Blood. 2019;134(Suppl. 1):5230.
   Google Scholar
• Leivonen S-K, Pollari M, Brück O, et al. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. Haematologica. 2019;104(2):338–346.
   PubMed Web of Science ®Google Scholar
• Autio M, Leivonen SK, Bruck O, et al. Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. Haematologica. 2020. doi:10.3324/haematol.2019.243626
   PubMed Web of Science ®Google Scholar
• Opinto G, Vegliante MC, Negri A, et al. The tumor microenvironment of DLBCL in the computational era. Front Oncol. 2020;10:351.
   PubMed Web of Science ®Google Scholar
• Mondello P, Fama A, Larson MC, Yang Z-Z, et al. Intrafollicular CD4+ T-cells as an independent predictor of early clinical failure in newly diagnosed follicular lymphoma. Blood. 2019;134(Suppl. 1):121.
   Google Scholar
• Tobin JWD, Keane C, Gunawardana J, et al. Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration. J Clin Oncol. 2019;37(34):3300–3309.
   PubMed Web of Science ®Google Scholar